Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
Conditions
Interventions
Placebo
Sotagliflozin
Locations
75
United States
Lexicon Investigational Site
Birmingham, Alabama, United States
Lexicon Investigational Site
Little Rock, Arkansas, United States
Lexicon Investigational Site
Escondido, California, United States
Lexicon Investigational Site
Greenbrae, California, United States
Lexicon Investigational Site
Huntington Beach, California, United States
Lexicon Investigational Site
La Jolla, California, United States
Start Date
March 1, 2015
Primary Completion Date
September 1, 2016
Completion Date
February 1, 2017
Last Updated
February 12, 2020
NCT07224321
NCT06474598
NCT07051005
NCT02734277
NCT06575426
NCT07356089
Lead Sponsor
Lexicon Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions